DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of the Earnings call conducted on May 10, 202315-05-2023
15-05-2023
Buy Dr. Reddy's Laboratories; target of Rs 5155: KR Choksey
KR Choksey is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5155 in its research report dated May 12, 2023.14-05-2023
Reduce Dr. Reddy's Laboratories; target of Rs 4500: Prabhudas Lilladher
Prabhudas Lilladher recommended Reduce rating on Dr. Reddy's Laboratories with a target price of Rs 4500 in its research report dated May 11, 2023.13-05-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation
Intimation regarding completion of US FDA audit of FTO SEZ PU2.12-05-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation
Intimation regarding completion of US FDA audit of FTO SEZ PU2.12-05-2023
After a weak quarter, Dr Reddy's stares at a gradual recovery
The path ahead seems tough with profit growth expected to moderate in FY24 after a strong performance in FY2312-05-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper advertisement regarding audited financial results for the quarter and year ended March 31, 202311-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Dr. Reddy's Laboratories Ltd.
Pharmaceuticals company Dr. Reddy's Laboratories announced Q4FY23 & FY23 results: Q4FY23: Gross margin at 57.2% (GG: 61.7%, PSAI: 25.2%). Gross margin increased by ~430 bps YoY, while it declined by ~210 bps QoQ. SG&A; expenses for Q4FY23 at Rs 18.0 billion, YoY increase of 15% and remained flat QoQ The impairment charge for Q4FY23 at Rs 0.5 billion R&D; expenses at Rs 5.4 billion, 8.5% of revenue Other operating income for Q4FY23 was Rs 0.3 billion Net finance income in Q4FY23 was Rs 0.8 billion. Profit before Tax for Q4FY23 is at Rs 13.3 billion Profit after Tax for Q4FY23 at Rs 9.6 billion. The effective tax rate for Q4FY23 has been at 27.6% as compared to 64.8% in Q4FY22. The previous year's ETR was higher due to the impairment charge impact. Diluted earnings per share for Q4FY23 is Rs 57.6 EBITDA for Q4FY23 at Rs 16.3 billion and the EBITDA margin at 25.9% Capital expenditure for Q4FY23 at Rs 2.6 billion Free cash flow for Q4FY23 at Rs 16.0 billion FY23: FY23 gross margin at 56.7%, an increase of ~360 bps over FY22 Selling, general & administrative (SG&A;) expenses for FY23 at Rs 68.0 billion, an increase of 10% on a YoY basis. SG&A; as a % of sales for FY23 was 27.7%, a decline of 130 basis points over FY22. The impairment charge for FY23 at Rs 0.7 billion Research & development (R&D;) expenses in FY23 at Rs 19.4 billion. As % to Revenues - FY23: 7.9% vs FY22: 8.2%. Other operating income for FY23 at Rs 5.9 billion compared to Rs 2.8 billion in FY22 Net Finance income for FY23 at Rs 2.9 billion compared to Rs 2.1 billion in FY22. The increase is primarily on account of higher foreign exchange gain in the current year as compared to FY22 and an increase in profit on the sale of mutual funds compared to FY22. Profit before Tax for FY23 at Rs 60.4 billion, YoY growth of 87% Profit after Tax for FY23 at Rs 45.1 billion. The effective tax rate for the year has been 25.3% as compared to 27.0% in FY22, due to changes in the company’s jurisdictional mix of earnings. Diluted earnings per share for FY23 is Rs 270.9 EBITDA for FY23 at Rs 73.1 billion and the EBITDA margin is 29.7% Capital expenditure for FY23 at Rs 11.3 billion Free cash flow for FY23 at Rs 40.1 billion Net cash surplus for the company at Rs 50.5 billion as on March 31, 2023 The Board has recommended payment of a dividend of Rs 40 per equity share of face value Rs 5/- each (800% of face value) for FY23 subject to the approval of the members of the company Result PDF11-05-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the link of the audio recording of the Earnings call for the quarter and year ended March 31, 2023, conducted on May 10, 202311-05-2023
Dr Reddy's Q4 net profits grow multifold driven by good India and US performance
The company's Ebitda at 1,631.2 crore improved significantly over 1,298.0 crore in Q4 FY2210-05-2023